D
콜마바이오텍
215380KOSDAQ33.5 / 100
Reference Date: 2026-09-08
Financial Score9.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure7.0 / 15
AI Analysis: ROE is below the industry average, Operating Profit is on a declining trend. Declined 8.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Ujeong Bio operates in two main business areas: Bio Business and Infection Control Business, offering services such as biological indicator (BI) testing, genetic toxicity evaluation, and SPR analysis. The biotech industry is growing rapidly due to advancements in oncology drugs, immunotherapy, and obesity treatments, supported by government initiatives and increasing demand for pharmaceutical innovation.
Number of Employees
127people
Average Salary
50.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.54Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-21.03Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
142.65Industry Average 100.002.0Point
Higher than industry avg (caution)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼0.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼89.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (26%)
Current 2,145Won52-week high 3,60552-week low 1,629
1-month return1.0Point
1m -8.14% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
5 totalPositive 0Neutral 4Negative 1
- Neutral전환가액의조정2026-08-31
- Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-28
- Neutral기타경영사항(자율공시) (소규모합병 승인 이사회 결의(주주총회 갈음) 결과 보고)2026-08-19
- Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
- Neutral반기보고서 (2026.06)2026-08-14